Hadighi R, Boucher P, Khamesipour A, Meamar A R, Roy G, Ouellette M, Mohebali M
Department of Parasitology, Faculty of Medicine, Iran University of Medical Sciences, 14496, Tehran, Iran.
Parasitol Res. 2007 Oct;101(5):1319-22. doi: 10.1007/s00436-007-0638-0. Epub 2007 Jul 5.
Cutaneous leishmaniasis (CL) is a major health problem in endemic areas of Iran. The pentavalent antimony (SbV) based drug Glucantime is the first line of treatment for CL in Iran, but recently SbV-resistant Leishmania tropica isolates derived from unresponsive patients were reported. We show in this study that these resistant parasites are cross-resistant to the other SbV-containing drug Pentostam and at least for one isolate also to amphotericin B. However, these resistant isolates were shown to be sensitive to miltefosine and paromomycin. The latter two drugs could thus be useful alternatives for the treatment of leishmaniasis in Iran even for SbV-resistant isolates.
皮肤利什曼病（CL）是伊朗流行地区的一个主要健康问题。基于五价锑（SbV）的药物葡糖酸锑钠是伊朗治疗CL的一线药物，但最近有报道称，从无反应患者中分离出了对SbV耐药的热带利什曼原虫。我们在本研究中表明，这些耐药寄生虫对另一种含SbV的药物喷他脒呈交叉耐药，并且至少对一株分离株而言，对两性霉素B也呈交叉耐药。然而，这些耐药分离株对米替福新和巴龙霉素敏感。因此，后两种药物即使对于对SbV耐药的分离株，也可能是治疗伊朗利什曼病的有用替代药物。
